The FATE Paradox: Analysts Bullish But Forecast -12.43% Fall
March 05, 2020 at 10:12 AM EST
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Fate Therapeutics Inc (FATE). The average 12-month price target for FATE — averaging the work of 14 analysts — reveals an average price target of $26.93/share..
